[go: up one dir, main page]

CO5680420A2 - Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4 - Google Patents

Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4

Info

Publication number
CO5680420A2
CO5680420A2 CO05003399A CO05003399A CO5680420A2 CO 5680420 A2 CO5680420 A2 CO 5680420A2 CO 05003399 A CO05003399 A CO 05003399A CO 05003399 A CO05003399 A CO 05003399A CO 5680420 A2 CO5680420 A2 CO 5680420A2
Authority
CO
Colombia
Prior art keywords
compounds
aminobenzenofuran
indazol
phosphodiesterase
inhibitors
Prior art date
Application number
CO05003399A
Other languages
English (en)
Inventor
Richard A Schumacher
Allen Hopper
Tehim Ashok
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of CO5680420A2 publication Critical patent/CO5680420A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I o II: en donde R1 es H, alquilo con entre 1 y 8 átomos de carbono, que es ramificado o no ramificado y que está insustituido o sustituido una o más veces por halógeno,cicloalquilo con entre 3 y 10 átomos de carbono, que está insustituido o sustituido una o más veces por halógeno, hidroxi, oxo, ciano, alquilo con entre 1 y 4 átomos de carbono, alcoxi con entre 1 y 4 átomos de carbono, o sus combinaciones, o un grupo heterocíclico, que es saturado, parcialmente saturado o insaturado, con entre 5 y 10 átomos en el anillo en donde al menos 1 átomo en el anillo es un átomo de N, O o S, que está insustituido o sustituido una o más veces por halógeno, alquilo, hidroxi, alcoxi, alcoxialcoxi, nitro, metilendioxi, etilendioxi, trifluorometilo, amino, aminometilo, aminoalquilo, aminoalcoxi dialquilamino, hidroxialquilo, ácido hidroxámico, tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, o sus combinaciones, R2 es H, o alquilo con entre 1 y 4 átomos de carbono, que es ramificado o no ramificado y que está insustituido o sustituido una o más veces por halógeno, ciano, y/o C1-4-alcoxi, y donde uno o más grupos -CH#2CH#2- se reemplazan opcionalmente en cada caso por -CH=CH- o -C=C-, R3 es H,alquilo con entre 1 y 8 átomos de carbono, que es ramificado o no ramificado y que está insustituido o sustituido una o más veces con halógeno, ciano, C1-4-alcoxi, o sus combinaciones, un grupo carbociclo-alquilo parcialmente insaturado en donde la porción carbocíclica tiene entre 5 y 14 átomos de carbono y la porción alquilo que es ramificada o no ramificada tiene entre 1 y 5 átomos de carbono, ...
CO05003399A 2002-07-19 2005-01-18 Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4 CO5680420A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39672602P 2002-07-19 2002-07-19

Publications (1)

Publication Number Publication Date
CO5680420A2 true CO5680420A2 (es) 2006-09-29

Family

ID=30770939

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05003399A CO5680420A2 (es) 2002-07-19 2005-01-18 Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4

Country Status (19)

Country Link
US (2) US7655802B2 (es)
EP (1) EP1549619B1 (es)
JP (1) JP2006502995A (es)
CN (2) CN101423497A (es)
AT (1) ATE421505T1 (es)
AU (2) AU2003256601B2 (es)
BR (1) BR0313000A (es)
CA (1) CA2492911A1 (es)
CO (1) CO5680420A2 (es)
DE (1) DE60325984D1 (es)
ES (1) ES2323688T3 (es)
HR (1) HRP20050082A2 (es)
IL (1) IL166164A0 (es)
MX (1) MXPA05000825A (es)
NO (1) NO20050871L (es)
NZ (1) NZ537725A (es)
RU (1) RU2354648C2 (es)
WO (1) WO2004009557A1 (es)
ZA (1) ZA200500436B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
WO2006128847A2 (en) * 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
PL1981851T3 (pl) 2006-01-31 2012-07-31 Array Biopharma Inc Inhibitory kinazy i sposoby ich stosowania
RU2477282C2 (ru) 2007-08-17 2013-03-10 Эл Джи Лайф Сайенсиз Лтд. Соединения индола в качестве ингибиторов клеточного некроза
US10564798B2 (en) * 2007-09-26 2020-02-18 Autodesk, Inc. Navigation system for a 3D virtual scene
SI2221058T1 (sl) * 2007-11-30 2013-11-29 Chi, Yu-Fen Zdravilo proti melanholiji pripravljeno iz materialov jujuba cAMP
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20150065191A (ko) * 2012-11-08 2015-06-12 화이자 인코포레이티드 헤테로방향족 화합물 및 도파민 d1 리간드로서 이의 용도
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN118994068A (zh) * 2023-05-19 2024-11-22 上海中医药大学 磷酸二酯酶4抑制剂、其药物组合物及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE580519C (de) * 1932-02-26 1933-07-12 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 2-Oxy-3-arylaminonaphthalinen
US3259623A (en) 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
GB1337389A (en) 1969-12-10 1973-11-14 Ici Ltd Pyrimidine derivatives
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2244520B1 (es) 1973-07-06 1977-02-04 Ugine Kuhlmann
US4524373A (en) 1982-02-24 1985-06-18 Kanzaki Paper Manufacturing Co., Ltd. Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material
GB2202434B (en) * 1987-03-25 1990-03-28 Tachi S Co Apparatus for manufacturing a seat
US5221682A (en) * 1989-06-28 1993-06-22 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5204226A (en) 1991-03-04 1993-04-20 International Business Machines Corporation Photosensitizers for polysilanes
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
JP3634861B2 (ja) 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
JP3775684B2 (ja) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (es) 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU6971894A (en) 1993-05-27 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206789A (ja) 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd コンブレタスタチン類縁化合物
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JP3806144B2 (ja) 1993-12-22 2006-08-09 セルテック セラピューティックス リミテッド 三置換フェニル誘導体、その調製方法とホスホジエステラーゼ（ｉｖ型）阻害剤としてのその使用
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
PL192561B1 (pl) * 1996-04-19 2006-11-30 Akzo Nobel Nv Podstawione benzyloaminy, ich zastosowanie i kompozycja farmaceutyczna
ES2201299T3 (es) 1996-06-25 2004-03-16 Pfizer Inc. Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`.
BR9712005A (pt) 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US5919937A (en) 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
AU751453C (en) 1997-11-25 2003-04-10 Warner-Lambert Company Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
JP4754068B2 (ja) 1997-12-24 2011-08-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
WO2000018761A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP2002537383A (ja) 1999-02-25 2002-11-05 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害化合物、組成物および治療方法
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
KR100666514B1 (ko) 1999-05-21 2007-02-28 브리스톨-마이어즈 스퀴브 컴페니 키나제의 피롤로트리아진 저해제
JP4434362B2 (ja) * 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
AU1899501A (en) * 1999-11-27 2001-06-04 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives
ES2254077T3 (es) 1999-12-18 2006-06-16 Wella Aktiengesellschaft Derivados 2-aminoalquil-1,4-diaminobenceno y su utilizacion para el teñido de fibras.
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
CN1307173C (zh) * 2000-12-21 2007-03-28 葛兰素集团有限公司 作为血管生成调节剂的嘧啶胺
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
YU57603A (sh) 2001-01-22 2006-08-17 Memory Pharmaceuticals Corporation Inhibitori fosfodiesteraze 4
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US20030149052A1 (en) 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
MXPA05000827A (es) 2002-07-19 2005-08-29 Memory Pharm Corp Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
EP1569908B1 (en) 2002-11-19 2010-09-15 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs

Also Published As

Publication number Publication date
AU2003256601A1 (en) 2004-02-09
NO20050871L (no) 2005-02-18
US20070123570A1 (en) 2007-05-31
US7655802B2 (en) 2010-02-02
RU2354648C2 (ru) 2009-05-10
ZA200500436B (en) 2006-07-26
BR0313000A (pt) 2005-07-12
HK1081194A1 (en) 2006-05-12
EP1549619A1 (en) 2005-07-06
MXPA05000825A (es) 2005-08-29
DE60325984D1 (de) 2009-03-12
AU2010200233A1 (en) 2010-02-11
ATE421505T1 (de) 2009-02-15
RU2005104820A (ru) 2005-10-10
AU2003256601B2 (en) 2009-10-29
CN100381425C (zh) 2008-04-16
HRP20050082A2 (en) 2005-06-30
JP2006502995A (ja) 2006-01-26
CN1668602A (zh) 2005-09-14
US20100093806A1 (en) 2010-04-15
ES2323688T3 (es) 2009-07-23
WO2004009557A1 (en) 2004-01-29
NZ537725A (en) 2006-08-31
IL166164A0 (en) 2006-01-15
EP1549619B1 (en) 2009-01-21
CN101423497A (zh) 2009-05-06
CA2492911A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
YU57603A (sh) Inhibitori fosfodiesteraze 4
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0207302A (pt) Trifluorometilpurinas como inibidores da fosfodiesterase 4
DE60233884D1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
BR0313969A (pt) Inibidores de oxitocina
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BRPI0416678A (pt) pirazolpirimidinas
ATE399169T1 (de) Imidazopyridinderivate als inhibitoren der induzierbaren no-synthase
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
DE602004002464D1 (de) IMIDAZOi4,5-BöCHINOLINDERIVATE UND IHRE VERWENDUNG ALS INHIBITOREN DER INDUZIERBAREN NO-SYNTHASE

Legal Events

Date Code Title Description
FC Application refused